

**PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

First Applicant:	Watkins, Jeffrey D.	Group Art Unit: 1644
Serial No.:	10/553,938	Examiner: Ron Schwadron, Ph.D.
Filing Date:	October 21, 2005	Conf No.: 8652
For:	CD20 Binding Molecules	
Docket No.:	X-16760A	

**REQUEST FOR CONTINUED EXAMINATION UNDER C.F.R. § 1.114**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This paper is filed in response to the Advisory Action mailed to Applicant on June 15, 2011 (hereinafter, the “Advisory Action”) in regards to the patent application captioned above. Applicant hereby makes the following submission under 37 CFR 1.114(c) in connection with the Request for Continued Examination (RCE) pursuant to 37 CFR 1.114(b) and (c) filed concurrently with this submission for the above-identified patent application.

The disposition of the claims was formally acknowledged by the Examiner in the Advisory Action. Briefly, Claims 34, 48, and 51 are pending and currently stand rejected. Claims 1-33, 35-39, and 49-50 were canceled previously. Claims 40-47 were withdrawn from consideration.

In response to the Final Office Action dated April 1, 2011 (hereinafter, the “Final Office Action”), the Applicant submitted an Amendment and Response to Final Rejection on June 1, 2011 (hereinafter, the “Response to Final Rejection”). The Response to Final Rejection included both a Terminal Disclaimer under 37 C.F.R. § 1.321 and a Declaration by Dr. Derrick Witcher under 37 C.F.R. § 1.132 (hereinafter, the “Witcher Declaration”). However, as indicated in the Advisory Action, “the proposed amendment(s) filed after [the] final rejection . . . were not entered” because they allegedly “raise new issues that would require further consideration.”

Pursuant to MPEP § 706.07(h) III. D. (Treatment of Proper RCE), any previously filed unentered amendments and amendments filed with the RCE will normally be entered. Such